Loading
Life sciences · Journal article
Pathogens · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a critical-priority pathogen associated with severe healthcare-associated infections, limited therapeutic options, and high mortality, particularly among critically ill patients. This narrative review summarises current and emerging therapeutic strategies for CRAB infections, with particular emphasis on pharmacokinetic/pharmacodynamic (PK/PD) considerations and antimicrobial exposure at different sites of infection. Sulbactam-containing regimens remain central to CRAB treatment, with sulbactam–durlobactam recommended by the 2026 Infectious Diseases Society of America (IDSA) guidance in combination with imipenem–cilastatin or meropenem for invasive CRAB infection, with definitive selection informed by susceptibility results and infection site. High-dose ampicillin–sulbactam, cefiderocol, polymyxins, and tetracycline derivatives retain important but context-dependent roles, while adequate source control remains essential. Importantly, antimicrobial susceptibility alone may not predict therapeutic success, particularly at sites where adequate drug exposure is difficult to achieve. Infection-site pharmacokinetics are therefore discussed to support rational treatment selection in pulmonary, bloodstream, urinary, central nervous system, and deep-seated infections. Emerging agents, including zosurabalpin, apramycin, zifanocycline, and next-generation polymyxins, may expand future treatment options. Nebulised antibiotics, bacteriophages, vaccines, and monoclonal antibodies represent additional evolving strategies, although robust evidence of clinical benefit remains limited. Optimizing CRAB therapy requires integration of susceptibility data, PK/PD principles, infection-site drug exposure, toxicity, and effective source control.